Journal article

Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: Results of a randomized controlled trial

P O'Hare, R Bilous, T Mitchell, CJ O'Callaghan, G Viberti, R Willoughby, J Riley, AM Robinson, JP Reckless, F Havard, M Sampson, A Lloyd, T Williams, J Vora, P Chattington, K Hampson, H Ibrahim, L Borthwick, C Russell, D Barnes Show all

Diabetes Care | Published : 2000

Abstract

OBJECTIVE - To assess if low (1.25 mg) and/or standard (5 mg) doses of the ACE inhibitor ramipril could prevent progression of microalbuminuria (incipient diabetic nephropathy) in normotensive type 1 diabetic patients. RESEARCH DESIGN AND METHODS - This study, using a multicenter randomized placebo-controlled double-blind parallel group, was conducted over 2 years in 28 outpatient diabetic clinics in the U.K. and Ireland. We screened 334 type 1 diabetic patients with suspected microalbuminuria and normal blood pressure; of these, 140 patients 18-65 years of age with a diagnosis of type 1 diabetes and persistent microalbuminuria, defined as urinary albumin excretion rate (AER) of 20-200 μg/mi..

View full abstract

University of Melbourne Researchers